SHORT COURSE

Wednesday Morning - March 24, 8:00 AM - 12:00 Noon





63. New Concepts in the Diagnosis and Classification of Extranodal Lymphomas

Yaso Natkunam, M.D, Ph.D, Stanford University School of Medicine, Stanford, CA, Eric D. Hsi, M.D., Cleveland Clinic Foundation, Cleveland, OH, and Daniel A. Arber, M.D., Stanford University School of Medicine, Stanford, CA

Up to 40% of lymphomas occur at sites other than the lymph node. Their recognition, diagnosis and classification are challenging because of their unusual clinical presentations and the lack of architectural landmarks typical of their nodal counterparts. In addition, there is overlap with non-hematopoietic tumors at various anatomic locations. The course content is designed to provide a comprehensive diagnostic approach to extranodal lymphomas for general surgical pathologists, hematopathologists and pathology trainees including hematopathology fellows.

The course will consist of case presentations that highlight differential diagnostic considerations and the selection of pertinent ancillary testing (immunohistochemistry, flow cytometry and molecular genetic methods including karyotyping, PCR and FISH) based on the new WHO and EORTC classifications. Extranodal lymphomas from the following anatomic sites will be discussed: 1) Gastrointestinal tract, 2) Nasal/upper aerodigestive system, 3) Salivary glands and ocular adnexa, 5) central nervous system, 6) mediastinum, and 7) extranodal lymphomas that present without mass lesions.

Virtual slides of extranodal lymphomas together with clinical histories will be provided on the USCAP website prior to the meeting. All registrants will also receive a CD including the PowerPoint presentations and a detailed syllabus with bibliography.

Upon completion of this course, participants should be able to: 1) recognize the salient features of extranodal lymphomas occurring at various anatomic locations, 2) be familiar with an integrated approach to the diagnosis of extranodal lymphomas that incorporates morphologic approaches with appropriate ancillary studies, 3) understand the changes in the revised WHO classification of lymphoid neoplasms and the impact of immunohistologic and molecular markers on diagnosis and classification.

(New Course) This course may be used for CME credits or SAM's credits.